Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.51 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.51 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.51 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.51 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.51 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5011461 | 0.93 | CACNA2D1 (0.57) | MAOBNPSR1MAPTKMT2AALDH1A1 | |
| SCHEMBL5721835 | 0.83 | MAOB (0.59) | MAOBNPSR1MAPTKMT2AALDH1A1 | |
| SCHEMBL12121366 | 0.81 | HRH3 (0.60) | ALDH1A1HPGD | |
| SCHEMBL2142414 | 0.79 | CYP3A4 (0.45) | MAOBNPSR1MAPTKMT2AALDH1A1 | |
| SCHEMBL9327563 | 0.78 | ALDH1A1 (0.71) | MAOBNPSR1MAPTKMT2AALDH1A1 | |
| SCHEMBL13994898 | 0.78 | CACNA2D1 (0.60) | MAOBMAPTKMT2AALDH1A1TSHR | |
| SCHEMBL16599230 | 0.77 | HRH4 (0.67) | MAOBNPSR1MAPTKMT2AL3MBTL1 | |
| SCHEMBL17954144 | 0.77 | HRH4 (0.56) | MAOBNPSR1MAPTKMT2AALDH1A1 | |
| SCHEMBL17954147 | 0.77 | HRH4 (0.56) | MAOBNPSR1MAPTKMT2AALDH1A1 | |
| SCHEMBL12121414 | 0.76 | HPGD (0.62) | ALDH1A1L3MBTL1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3145547-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR MALFORMATION | IFOM Fondazione Istituto Firc di Oncologia Molecolare (IT) | 2017-03-29 | — | — | EP | claimed |
| CN-106535937-A | Methods and compositions for the treatment of vascular malformation | 意大利癌症研究基金会分子肿瘤学研究所(IFOM) | 2017-03-22 | — | — | CN | claimed |
| US-20170027896-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR MALFORMATION | IFOM - FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2017-02-02 | — | — | US | claimed |
| WO-2015155335-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR MALFORMATION | IFOM - FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2015-10-15 | — | — | WO | claimed |
| US-20100292170-A1 | METHODS FOR DIAGNOSING AND TREATING PELVIC PAIN DISORDERS VIA BETA-CATENIN | UNIVERSITY OF ROCHESTER (US) | 2010-11-18 | — | — | US | claimed |
| WO-2009061847-A2 | METHODS FOR DIAGNOSING AND TREATING PELVIC PAIN DISORDERS VIA BETA-CATENIN | UNIVERSITY OF ROCHESTER (US) | 2009-05-14 | — | — | WO | claimed |
| US-20040204477-A1 | Interaction inhibitors of tcf-4 with beta-catenin | PHARMACIA ITALIA S.P.A. (IT) | 2004-10-14 | — | — | US | claimed |
| EP-1406889-A2 | INTERACTION INHIBITORS OF TCF-4 WITH BETA-CATENIN | Pharmacia Italia S.p.A. (IT) | 2004-04-14 | — | — | EP | claimed |
| WO-2003006447-A2 | INTERACTION INHIBITORS OF TCF-4 WITH BETA-CATENIN | PHARMACIA ITALIA SPA (IT) | 2003-01-23 | — | — | WO | claimed |
| EP-3145547-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR MALFORMATION | IFOM Fondazione Istituto Firc di Oncologia Molecolare (IT) | 2017-03-29 | — | — | EP | disclosed |
| CN-106535937-A | Methods and compositions for the treatment of vascular malformation | 意大利癌症研究基金会分子肿瘤学研究所(IFOM) | 2017-03-22 | — | — | CN | disclosed |
| US-20170027896-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR MALFORMATION | IFOM - FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2017-02-02 | — | — | US | disclosed |
| WO-2015155335-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR MALFORMATION | IFOM - FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE (IT) | 2015-10-15 | — | — | WO | disclosed |
| US-8415108-B2 | Methods for diagnosing interstitial cystitis via nuclear localization of beta-catenin | UNIVERSITY OF ROCHESTER (US) | 2013-04-09 | — | — | US | disclosed |
| US-20100292170-A1 | METHODS FOR DIAGNOSING AND TREATING PELVIC PAIN DISORDERS VIA BETA-CATENIN | UNIVERSITY OF ROCHESTER (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2009061847-A2 | METHODS FOR DIAGNOSING AND TREATING PELVIC PAIN DISORDERS VIA BETA-CATENIN | UNIVERSITY OF ROCHESTER (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20040204477-A1 | Interaction inhibitors of tcf-4 with beta-catenin | PHARMACIA ITALIA S.P.A. (IT) | 2004-10-14 | — | — | US | disclosed |
| EP-1406889-A2 | INTERACTION INHIBITORS OF TCF-4 WITH BETA-CATENIN | Pharmacia Italia S.p.A. (IT) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003006447-A2 | INTERACTION INHIBITORS OF TCF-4 WITH BETA-CATENIN | PHARMACIA ITALIA SPA (IT) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204477-A1 | Interaction inhibitors of tcf-4 with beta-catenin | TCF4, TCF7, TCF7L2 | MAOB 3240/4885NPSR1 4507/4885MAPT 3189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.